Propensity score matching analysis: incidence and risk factors for “stardust” gastric mucosa, a novel gastric finding potentially induced by vonoprazan

Abstract

SummaryBackgroundVonoprazan, a potassium‐competitive acid blocker, is used for acid‐related diseases. Occasionally, small white protrusions called “stardust” gastric mucosa have been detected in the stomachs of some patients taking vonoprazan.AimsTo determine the incidence of, and risk factors for, stardust gastric mucosa potentially induced by vonoprazanMethodsIn this study, we enrolled 19 503 patients who underwent endoscopy at our hospital between 2016 and 2019. Using propensity score matching, we retrospectively compared patients who received and did not receive vonoprazan. The two groups were matched for age, sex, history of proton pump inhibitor use, and atrophic gastritis.ResultsAfter 1:1 propensity score matching, each group comprised 2516 patients. Stardust gastric mucosa was detected significantly more often in the stomachs of patients receiving vonoprazan than those who had not received vonoprazan (4.9% vs 0.2%, P < 0.001). Its location was 70.7% in the upper third of the stomach, 29.3% in the middle third and none in the lower third. Histologically, this lesion had a mucus pool within a dilated duct surrounded by flattened glandular epithelium. The cumulative incidence rate of stardust gastric mucosa at 1, 2 and 3 years was 4.6%, 16.5% and 26.2%, respectively. The factors independently associated with the presence of stardust gastric mucosa were >205 days of vonoprazan oral intake (odds ratio [OR]: 6.99, 95% confidence interval [CI]: 4.60‐10.88) and female sex (OR: 1.75, 95% CI: 1.20‐2.58).ConclusionsStardust gastric mucosa appeared more frequently in the stomachs of patients taking vonoprazan.